OzStar's case study data demonstrates the effectiveness of the OZ101 combination therapy with sulphonylurea in type 2
diabetes patients. Results indicate a
substantial and clinically significant (i) reduction in fasting blood glucose levels,
(ii) reduction in sulphonylurea side effects, (iii) significant extension of the duration of sulphonylurea efficacy, collectively
providing a positive impact on patient's quality of life.

OzStar's initial clinical case studies were completed with eight type 2 diabetes patients, four of which were on
sulphonylurea monotherapy, with uncontrolled blood glucose levels of greater than 7 mmol/L. The addition of OzStar's
active OZ101 ingredient as a supplement to their existing sulphonylurea therapy resulted in a clear reduction in fasting
glucose levels (FGL). These initial human case studies has suggest that the proprietary combination therapy can
achieve near-normal FGL levels (between 5.5 to 7mmol/L) within 6 months.

Figure 1 below depicts near-normalisation of FGL after consumption of OZ101 in a patient being treated with the
sulphonylurea drug, glibenclamide (Glyburide), monotherapy with uncontrolled blood glucose levels.

This add-on therapy also resulted in a reduced of monthly fluctuation of FGL and a clinically significant reduction in
blood HbA1c level from 7.8% to 7.2% after 6 months of therapy. The patients reported that this combination therapy
reduced the side effects of sulphonylurea use such as hypoglycemic episodes and weight gain and led to a significant
improvement in quality of life.

       OzStar Therapeutics

           OzStar Therapeutics Pty Ltd © 2016                                                   Privacy Policy                                              
Case Studies